Login to Your Account

Domain, Merck target adenosine receptors in $257M I-O pact

By Cormac Sheridan
Staff Writer

Monday, January 23, 2017

DUBLIN – Domain Therapeutics SA could receive up to €240 million in an up-front payment, potential milestones and eventual sales royalties from a licensing deal with Merck KgaA on its preclinical program of adenosine receptor modulators.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription